Capital Impact Advisors LLC Buys 2,821 Shares of Twist Bioscience Co. (NASDAQ:TWST)

Capital Impact Advisors LLC grew its stake in Twist Bioscience Co. (NASDAQ:TWST) by 16.1% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 20,380 shares of the company’s stock after buying an additional 2,821 shares during the period. Twist Bioscience accounts for about 2.8% of Capital Impact Advisors LLC’s holdings, making the stock its 5th largest position. Capital Impact Advisors LLC’s holdings in Twist Bioscience were worth $1,004,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. American International Group Inc. boosted its position in shares of Twist Bioscience by 0.8% during the 1st quarter. American International Group Inc. now owns 28,506 shares of the company’s stock valued at $978,000 after acquiring an additional 213 shares in the last quarter. Caprock Group LLC boosted its position in shares of Twist Bioscience by 2.9% during the 2nd quarter. Caprock Group LLC now owns 7,851 shares of the company’s stock valued at $387,000 after acquiring an additional 220 shares in the last quarter. Arizona State Retirement System boosted its position in shares of Twist Bioscience by 1.9% during the 2nd quarter. Arizona State Retirement System now owns 16,187 shares of the company’s stock valued at $798,000 after acquiring an additional 308 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its position in shares of Twist Bioscience by 3.5% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 9,279 shares of the company’s stock valued at $457,000 after acquiring an additional 312 shares in the last quarter. Finally, CWM LLC boosted its position in shares of Twist Bioscience by 27.4% during the 2nd quarter. CWM LLC now owns 2,437 shares of the company’s stock valued at $120,000 after acquiring an additional 524 shares in the last quarter.

Twist Bioscience Trading Down 1.5 %

Twist Bioscience stock opened at $46.39 on Monday. The firm has a market capitalization of $2.70 billion, a P/E ratio of -13.81 and a beta of 1.76. The business has a 50-day moving average of $46.31 and a 200-day moving average of $43.42. Twist Bioscience Co. has a 1 year low of $14.42 and a 1 year high of $60.90.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings results on Friday, August 2nd. The company reported ($1.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.71). The firm had revenue of $81.50 million during the quarter, compared to analyst estimates of $77.40 million. Twist Bioscience had a negative net margin of 74.63% and a negative return on equity of 32.17%. The business’s revenue was up 27.7% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.01) earnings per share. Research analysts anticipate that Twist Bioscience Co. will post -3.13 EPS for the current fiscal year.

Analyst Ratings Changes

TWST has been the topic of several recent research reports. The Goldman Sachs Group lifted their target price on shares of Twist Bioscience from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Tuesday, July 9th. TD Cowen boosted their target price on shares of Twist Bioscience from $55.00 to $65.00 and gave the stock a “buy” rating in a research note on Thursday, June 13th. JPMorgan Chase & Co. boosted their target price on shares of Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a research note on Monday, August 5th. Barclays dropped their target price on shares of Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a research note on Monday, August 5th. Finally, Robert W. Baird boosted their target price on shares of Twist Bioscience from $40.00 to $46.00 and gave the stock an “outperform” rating in a research note on Monday, August 5th. One research analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. According to MarketBeat, Twist Bioscience has an average rating of “Moderate Buy” and an average price target of $50.88.

Insider Activity at Twist Bioscience

In related news, CFO Adam Laponis sold 842 shares of the stock in a transaction that occurred on Tuesday, July 9th. The shares were sold at an average price of $48.91, for a total value of $41,182.22. Following the sale, the chief financial officer now directly owns 73,602 shares in the company, valued at approximately $3,599,873.82. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Twist Bioscience news, CFO Adam Laponis sold 842 shares of the firm’s stock in a transaction that occurred on Tuesday, July 9th. The shares were sold at an average price of $48.91, for a total transaction of $41,182.22. Following the sale, the chief financial officer now directly owns 73,602 shares in the company, valued at approximately $3,599,873.82. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Emily M. Leproust sold 5,139 shares of the firm’s stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $39.93, for a total transaction of $205,200.27. Following the sale, the chief executive officer now owns 499,593 shares in the company, valued at $19,948,748.49. The disclosure for this sale can be found here. Insiders have sold 17,386 shares of company stock worth $770,915 in the last ninety days. Company insiders own 3.92% of the company’s stock.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.